Specialized HPAPI and cytotoxic oral solid dose manufacturing in purpose-built high-containment facilities, ensuring safety, compliance, and reliable commercial supply.
Companion Animal Health
Specialized development and manufacturing of oral solid dose products for animal health, supporting the growing veterinary pharmaceutical market.
Oral Solid Dose Development
End-to-end OSD development and scale-up for tablets, capsules, and complex formulations - from early-stage design to global commercial supply.
Regulatory & Compliance
Smooth, efficient tech transfer and comprehensive regulatory support across FDA, EU, and PMDA pathways to accelerate development and reduce onboarding risk.
Advanced Softgel Capabilities
Specialist softgel formulation and manufacturing to maximize bioavailability, improve stability, and deliver patient-centric dosage solutions.
​
OSD Lifecycle Support
Seamless progression from clinical batch manufacturing to full commercial OSD production, ensuring continuity, quality, and predictable scale-up.
​
Packaging &
Serialization
Integrated clinical and commercial packaging, serialization, and artwork management to ensure compliant, traceable, and market-ready drug products.
Small-Batch & Flexiblility
Agile, small-batch OSD and softgel manufacturing to support early development, niche products, and cost-efficient pilot runs.
​
Why Partner's Choose Eirgen
High-Potency & Containment Specialists
Purpose-built high-containment suites engineered for safe, compliant HPAPI and cytotoxic manufacturing.
Our Customer Experience in Numbers
8.82
Overall Customer
Satisfaction Score
*Scored out of 10*
48%
Rated Our Technical
Capabilities as Excellent
65%
Reported That Eirgen
Exceeded Expectations
100%
Expressed High Confidence in our Product Quality & GMP-Compliance
Achieving Excellence, Together.
20
Since 2005, Eirgen Pharma has been a trusted partner in the development and manufacturing of high-potency pharmaceuticals. With 20 years experience, we continue to deliver innovation, quality, and global impact.
120
Eirgen Pharma proudly partners with over 120 pharmaceutical companies across 60 countries. From development to delivery, we support our partners with reliable, high-quality solutions tailored to complex and high-potency products.
1 Billion
With current capacity at 520 million dosage unit annually, Eirgen Pharma is expanding fast. By 2027, our Waterford facility will deliver up to 1 billion units per year - doubling our output to meet growing global demands.
5
We hold 5 key regulatory approvals;
FDA, EMA, HPRA, PMDA, & MRHA
Our facilities meet the highest global standards - ensuring safe, compliant, and consistent delivery of complex high-potency pharmaceuticals worldwide.
Learn More About Us
Knowledge Hub
Information and resources, including news, whitepapers, and events.